News & Press
BioMotiv News & Press
BioMotiv announced today a new strategic partnership with Bristol-Myers Squibb. Under the partnership, BioMotiv and Bristol-Myers Squibb will form and fund new companies to develop novel therapeutics in disease areas where unmet medical needs remain.
OptiKira was awarded a $1.6M Phase II SBIR grant to support continued development of a therapy that has the potential to preserve vision in patients with retinitis pigmentosa (RP).
Koutif Therapeutics today announced that its IND application for KT-1002 has been cleared by FDA to begin a Phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s Disease.
BioMotiv and researchers from Rutgers, The State University of New Jersey, today announced the formation of a new biotech start-up, TamRx. The new company will focus on the development of a novel family of small molecule inhibitors designed to block tumor growth and stimulate the immune system to fight various forms of cancer.
Aro Biotherapeutics is a biotechnology company developing Centyrins, an innovative, next-generation protein drug platform that can be used for targeted drug delivery or as antibody-like therapeutics. The company has been launched with support from Johnson & Johnson Innovation and BioMotiv.
Click to view related media coverage.
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2019 Harrington Scholar-Innovator Award recipients. The projects supported by the awards include new therapeutics to treat metabolic disorders, autoimmune disorders and cancer, and new approaches to eradicate parasitic diseases in developing countries.
PharmaLex Group, one of the largest and most successful specialist providers of Development Consulting, Regulatory Affairs, Quality Management & Compliance and Pharmacovigilance, Epidemiology and Risk Management worldwide, has entered into a preferred partnership with BioMotiv, a mission-driven accelerator that advances breakthrough discoveries from research institutions into therapeutics for patients.
Sujana Biotech, a biotechnology company developing novel therapeutics to prevent inflammatory and vascular disorders, today announced new funding from the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke at the National Institutes for Health.
BioMotiv and Cure Network Dolby Acceleration Partners (CNDAP) have entered into an agreement to develop small molecules that could provide new treatment options for patients with neurological disorders, such as Dravet syndrome, other epilepsies, and Alzheimer’s disease.